Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci is a leader in tech-enabled biotech and next-gen biologics space with a business model that is underappreciated by investors. Their AI/ML technology platform and integrated drug discovery strategy have the potential to become a >$5B market cap company in the longer-term. Key highlights include diversified partnerships, a strong computational platform, best-in-class AI/ML engines, and impressive growth in forging new partnerships. However, risks to the rating and price target include clinical risks and competition, as well as financial risks related to the need for additional funds and uncertainty around the success of existing partnerships.

Bears say

Absci is known for its ML/AI drug discovery space and its lead product candidate, ABS-201, which has shown potential dosing of 2-3 injections over a 6-month period, making it an attractive option in the hair growth market. While the recent investment from Lilly and safety data in clinical trials are promising, there are still risks that could prevent the stock from reaching its $16 price target, such as competition and dilution.

Absci Corp (ABSI) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.